Microscopic skin scans may reveal how a new eczema drug reshapes the skin

NCT ID NCT07730788

Recruiting now Disease control Sponsor: Hôpitaux Drôme Nord Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study tests whether reflectance confocal microscopy (RCM), a noninvasive imaging technique, can detect structural changes in the skin of people with moderate-to-severe atopic dermatitis (eczema) who are treated with nemolizumab. Nemolizumab is an antibody that blocks IL-31, a protein involved in itching and inflammation. The goal is to see if RCM can provide a more detailed, objective measure of treatment response than standard clinical scores.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nemolizumab
What this could lead to: If successful, this could show that RCM is a reliable way to measure skin changes in atopic dermatitis, potentially improving how treatment response is evaluated.
What could go wrong: This is a very small, early-stage study with only 15 participants, so results may not apply broadly. The imaging technique is exploratory and not yet proven as a standard measure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD) ATOPIC DERMATITIS ECZEMA

Contacts and locations

Locations

Hôpitaux Drôme Nord
RECRUITING

Romans-sur-Isère, Drôme, 26100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.